Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and

Introdu 04/03/13		8, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,
Name	of entity	
BNK	Banking Corporation Limited	
ABN		
63 o8	87 651 849	
Ma (	the entity) give ASV the followin	a information
We (	the entity) give ASX the following	g information.
Part	the entity) give ASX the following  1 - All issues  oust complete the relevant sections (attack	
Part	t 1 - All issues	

<sup>+</sup> See chapter 19 for defined terms.

- **Principal** terms of the 3 +securities (e.g. if options, exercise price and expiry date; if \*securities, partly paid amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- (1) The same terms applicable to existing fully paid ordinary shares.
- (2) Performance rights are granted to employees pursuant to the BNK Equity Incentive Plan approved at the 26 November 2019 Annual General Meeting.

#### 250,000 FY20 Performance Rights

The Performance Rights vest as follows:

- 1. 30 September 2020 one third (83,335)
- 2. 30 September 2021 one third (83,335)
- 3. 30 September 2022 one third (83,330)

Subject to employees meeting relevant key performance conditions and approval by the BNK Remuneration Committee. Subject to eligibility of vesting being determined, the Participants may exercise vested Performance Rights for the period up until 29 November 2023. Any vested Performance Rights that are not exercised by 29 November 2023 will lapse on 30 November 2023.

Upon exercise, the Company will deliver the Participants fully paid ordinary Shares which will be either purchased on-market or issued from the capital of the Company at the election of the Board.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

(1) Yes

(2) Performance Rights are not quoted securities and do not rank equally with ordinary shares or any other class of quoted securities. Performance Rights do not confer a right to vote, a right to receive dividends or any other rights of a shareholder. Any ordinary share issued or transferred to the holder of a Performance Right upon vesting will rank equally from the date of allotment with other ordinary shares.

(1) Nil

- (2) The Eligible Employees were not required to pay for the grant of the Performance Rights and for each Performance Right that vests, the Eligible Employee will be entitled to receive one share in the Company without payment.
- (1) Exercise of vested performance rights.
- (2) 250,000 Performance Rights are granted as part of the Annual Performance Review of senior employees.

1 65

Not applicable

<sup>+</sup> See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval	(1) 125,000
	under rule 7.1	(2) 250,000
6d	Number of +securities issued	Nil
ou	with security holder approval	INII
	under rule 7.1A	
6e	Number of *securities issued	Nil
	with security holder approval	
	under rule 7.3, or another specific security holder approval	
	(specify date of meeting)	
	<b></b>	
6f	Number of *securities issued	Nil
	under an exception in rule 7.2	
6g	If +securities issued under rule	Not applicable
-8	7.1A, was issue price at least 75%	Two applicable
	of 15 day VWAP as calculated	
	under rule 7.1A.3? Include the +issue date and both values.	
	Include the source of the VWAP	
	calculation.	
6h	If *securities were issued under	Not applicable
	rule 7.1A for non-cash	
	consideration, state date on which valuation of	
	consideration was released to	
	ASX Market Announcements	
<i>-</i> .		
6i	Calculate the entity's remaining	See Annexure 1
	issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1	
	and release to ASX Market	
	Announcements	
7	<sup>+</sup> Issue dates	5 December 2019
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in	
	rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with	
	the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
82,540,399	Fully paid ordinary shares

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
1,291,677	BNK Long Term
	Equity Incentive
	Rights
180,000	FY18 Annual Performance Rights
100,000	FY19 Annual Performance Rights
366,668	Retention Performance Rights
250,000	FY20 Annual Performance Rights

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable

#### Part 2 - Pro rata issue

11	Is	security	holder	approva
	req	uired?		

Not applicable

Is the issue renounceable or non-renounceable?

Not applicable

Ratio in which the \*securities will be offered

Not applicable

<sup>+</sup>Class of <sup>+</sup>securities to which the offer relates

Not applicable

15 <sup>+</sup>Record date to determine entitlements

Not applicable

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
17	Policy for deciding entitlements in relation to fractions	Not applicable
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	Not applicable
19	Closing date for receipt of acceptances or renunciations	Not applicable
20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable
29	Date rights trading will end (if applicable)	Not applicable
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable
33	<sup>+</sup> Issue date	Not applicable
	<b>3 - Quotation of securitie</b> ed only complete this section if you are ap  Type of *securities (tick one)	
(a)	*Securities described in Part	1
(b)	•	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(a)

# Additional securities forming a new class of securities

Tick to docum	e you are providing the information or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(b)

Number of *securities for which *quotation is sought  *Class of *securities for which quotation is sought  Not applicable  Not applicable	
quotation is sought	
Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:	
<ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another +security, clearly identify that other +security)	
Number and +class of all +securities quoted on ASX (including the +securities in clause 38)  Number +Class Not applicable	

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 6 December 2019

(Company secretary)

paell

Print name: Malcolm Cowell

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	82,415,399	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	125,000 on 5 December 2019	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil	
"A"	82,540,399	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	12,381,060	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil	
• Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	12,381,060	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	12,381,060	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	82,540,399	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	8,254,040	
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
Notes:  • This applies to equity securities – not just ordinary securities  • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed  • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained  • It may be useful to set out issues of securities on different dates as separate line items		
"E"	Nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	8,254,040
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	8,254,040
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.